Skip to main content
    P

    Progyny Inc (PGNY)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NASDAQ

    $27.45
    -0.38 (-1.38%)

    Market Cap: $2.14B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    93%(27/29)
    Avg Surprise
    +98.57%
    Streak
    22 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.51
    Range$0.49 - $0.53
    9 analysts
    EPS RevisionsNo revisions (7d)
    1
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$0.52-2.7%
    60d ago$0.52-1.7%
    30d ago$0.510.0%
    7d ago$0.510.0%
    Current$0.51
    Revenue Consensus
    $341M
    Range$336M - $345M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.62
    Range$0.60 - $0.64
    9 analysts
    Revenue Consensus
    $359M
    Range$345M - $371M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.62---
    Sep 26EST
    		-$0.51---
    Jun 26
    Reported Aug 6
    		$0.34$0.28+21.43%Beat+78.9%
    Mar 26
    Reported May 7
    		$0.50$0.44+13.64%Beat+4.2%
    Dec 25
    Reported Feb 26
    		$0.14$0.13+7.69%Beat-66.7%
    Sep 25
    Reported Nov 6
    		$0.45$0.39+15.38%Beat+12.5%
    Jun 25
    Reported Aug 7
    		$0.19$0.17+11.76%Beat-55.8%
    Mar 25
    Reported May 8
    		$0.48$0.45+6.67%Beat+23.1%
    Dec 24
    Reported Feb 27
    		$0.42$0.37+13.51%Beat+223.1%
    Sep 24
    Reported Nov 12
    		$0.40$0.37+8.11%Beat+150.0%
    Jun 24
    Reported Aug 6
    		$0.43$0.40+7.50%Beat+186.7%
    Mar 24
    Reported May 9
    		$0.39$0.35+11.43%Beat+116.7%
    Dec 23
    Reported Feb 27
    		$0.13$0.11+18.18%Beat+333.3%
    Sep 23
    Reported Nov 7
    		$0.16$0.11+45.45%Beat+23.1%
    Jun 23
    Reported Aug 3
    		$0.15$0.10+50.00%Beat+66.7%
    Mar 23
    Reported May 8
    		$0.18$0.08+125.00%Beat+260.0%
    Dec 22
    Reported Feb 27
    		$0.03$0.01+200.00%Beat-80.0%
    Sep 22
    Reported Nov 3
    		$0.13$0.03+333.33%Beat-23.5%
    Jun 22
    Reported Aug 4
    		$0.09$0.01+800.00%Beat-52.6%
    Mar 22
    Reported May 5
    		$0.05$-0.02+350.00%Beat-66.7%
    Dec 21
    Reported Feb 28
    		$0.15$0.04+275.00%Beat+1400.0%
    Sep 21
    Reported Nov 4
    		$0.17$0.06+183.33%Beat+142.9%
    Jun 21
    Reported Aug 5
    		$0.19$0.09+111.11%Beat+2000.0%
    Mar 21
    Reported May 6
    		$0.15$0.09+66.67%Beat+200.0%
    Dec 20
    Reported Feb 24
    		$0.01N/A-83.33%Miss+0.0%
    Sep 20
    Reported Nov 5
    		$0.07$0.06+16.67%Beat+133.3%
    Jun 20
    Reported Aug 5
    		$-0.01$-0.02+50.00%Beat-133.3%
    Mar 20
    Reported May 12
    		$0.05$0.02+150.00%Beat-
    Dec 19
    Reported Mar 5
    		$0.01$0.02-50.00%Miss-
    Sep 19
    Reported Oct 25
    		$0.03$0.02+50.00%Beat-
    Jun 19
    Reported Aug 2
    		$0.03$0.02+50.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio19.20EV/EBITDA15.87x
    Price/FCF12.03xFCF Yield8.31%
    Profitability
    Profit Margin6.00%Operating Margin11.40%
    ROE16.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.14xQuick Ratio2.14x
    Trading Statistics
    Beta1.02Avg Volume1.22M
    52-Week High$33.0652-Week Low$16.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$27.10
    SMA 20$26.44
    SMA 50$26.51
    SMA 200$24.26
    EMA 10$27.19
    EMA 20$26.86
    EMA 50$26.90
    EMA 200$25.24

    MACD

    Line: 0.27Signal: 0.02Hist: 0.24

    ADX

    ADX: 30.5+DI: 27.2-DI: 11.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down52.0
    PSAR$24.97

    Bollinger Bands

    Upper Band$28.68
    Lower Band$24.20
    %B Position1694%(Upper)
    Band Width0.73

    RSI (14-Day)

    Neutral
    55.7

    Momentum Oscillators

    Stoch %K72.0
    Stoch %D78.5
    Williams %R-30.4
    ROC (10d)10.5%
    Momentum2.60
    CCI (20d)87.5
    MFI (14d)70.3

    Volatility Measures

    ATR (14d)$0.91(3.3%)
    StdDev (20d)1.12
    Hist Vol33.7%(Moderate)

    Volume Flow

    VWAP$27.77
    OBV28.7M
    AD Line14.0M
    CMF (20d)-0.068

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.8x
    VWMA (20d)$26.47

    Pivot Points

    R3$28.97
    R2$28.51
    R1$28.18
    Pivot Point$27.72
    S1$27.38
    S2$26.92
    S3$26.59

    Advanced Oscillators

    TSI8.70
    Ultimate Osc50.4
    KST16.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$350.51M$328.50M$318.40M$313.35M$332.87M$324.04M$298.43M$286.63M$304.09M$278.08M$269.94M$280.89M
    Cost of Revenue$261.21M$245.43M$241.52M$240.51M$253.90M$248.24M$235.00M$227.38M$235.81M$215.67M$213.05M$218.27M
    Gross Profit$89.30M$83.07M$76.88M$72.83M$78.97M$75.80M$63.43M$59.24M$68.28M$62.41M$56.89M$62.62M
    Operating Expenses$49.30M$47.69M$61.66M$51.31M$54.62M$51.63M$47.65M$46.79M$47.59M$43.88M$43.09M$44.44M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$31.22M$30.81M$43.67M$33.37M$36.21M$33.84M$32.03M$30.33M$31.17M$28.43M$28.18M$29.52M
    Operating Income$40.00M$35.38M$15.22M$21.53M$24.36M$24.17M$15.79M$12.46M$20.69M$18.52M$13.80M$18.19M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$41.14M$36.88M$17.85M$23.96M$27.08M$26.54M$17.66M$17.96M$25.07M$22.52M$16.26M$20.93M
    Income Tax Expense$13.09M$12.65M$5.37M$10.10M$9.96M$11.48M$7.13M$7.54M$8.58M$5.62M$2.79M$5.03M
    Net Income$28.05M$24.23M$12.48M$13.86M$17.11M$15.06M$10.53M$10.42M$16.48M$16.90M$13.47M$15.90M
    EBITDA$42.76M$38.37M$19.22M$25.23M$28.28M$27.64M$18.53M$18.80M$25.82M$23.23M$18.42M$21.51M
    EBIT$41.14M$36.88M$17.85M$23.96M$27.08M$26.54M$17.66M$17.96M$25.07M$22.52M$17.79M$20.93M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PGNY

    News

    Progyny presents menopause research and Barclays holds Progyny stock at USD 30.00

    Progyny will present new menopause research on October 22, 2026, expanding its healthcare offerings beyond fertility to include a full reproductive health continuum. Barclays has maintained a Hold rating on Progyny stock...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

    Progyny will present new research on menopause at The Menopause Society 2026 Annual Meeting. This presentation highlights Progyny's continued commitment to advancing understanding and solutions in women's health...

    Moomoo•10/15/26•Somewhat-Bullish

    Progyny unveils new menopause care research at ...

    Progyny will present new research on its employer-sponsored Menopause and Midlife program at The Menopause Society 2026 Annual Meeting. This study, conducted with Morehouse School of Medicine...

    Pluang•10/15/26•Neutral

    Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

    Progyny, Inc. will present new research at The Menopause Society 2026 Annual Meeting, evaluating outcomes from its employer-sponsored Menopause and Midlife program. The study...

    GlobeNewswire•10/15/26•Bullish

    Form 144 Progyny For: 14 October By Investing.com

    This article from Investing.com reports on a Form 144 filing for Progyny, dated October 14. It mentions Progyny (PGNY) stock performance, showing a 1.64% increase. The content is brief...

    Investing.com Nigeria•10/14/26•Neutral

    PGNY Valuation and Fair Value

    P/E
    19.2x
    Forward P/E
    11.8x
    EV/EBITDA
    15.9x
    P/FCF
    12.0x
    P/B
    4.7x
    See GNG's fair value

    PGNY Profitability: Margins, ROIC and FCF

    Gross margin
    24.6%
    Operating margin
    11.4%
    Net margin
    6.0%
    ROE
    16.2%
    FCF margin
    13.6%
    FCF yield
    8.3%

    PGNY Competitors

    CompanyTicker
    Disc Medicine Inc.IRON
    Dynavax Technologies CorporationDVAX
    Aurinia Pharmaceuticals IncAUPH
    Pharvaris BVPHVS
    Harmony Biosciences HoldingsHRMY
    Avadel Pharmaceuticals PLCAVDL
    Celldex Therapeutics IncCLDX
    Novavax IncNVAX

    Sector: Healthcare

    PGNY Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    9
    Hold
    2
    Sell
    0
    Strong Sell
    0

    PGNY Bull Case vs Bear Case

    Bull case

    • PGNY beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 83.3% of PGNY's analyst ratings are Buy or Strong Buy.

    PGNY Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    12.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.51
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 6 down

    Frequently Asked Questions About PGNY

    Does PGNY pay dividends?

    Progyny Inc (PGNY) does not currently pay a regular dividend.

    What is PGNY's P/E ratio?

    Progyny Inc has a price-to-earnings (P/E) ratio of 19.20.

    What is PGNY's market cap?

    Progyny Inc (PGNY) has a market capitalization of $2.14B with a current stock price of $27.45.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In